Systemic Gaps and Global Inequities Delay Safe Human Trials of Gene-Editing Therapies for the Brain
Original framing: “Gene-editing therapies not yet ready for human trials, Stanford expert says” — South China Morning Post
Scientific evidence indicates that off‑target effects and mosaicism remain significant challenges in neural tissue editing, especially given the brain’s cellular diversity and limited regenerative capacity. Robust longitudinal animal studies and advanced in‑silico modelling are required to predict long‑term outcomes before human exposure. Current data gaps justify the call for extended preclinical phases.
The delay in human brain gene‑editing trials is not merely a technical bottleneck but a symptom of entrenched power structures, historical missteps, and cultural blind spots.
By weaving Indigenous relational ethics, historical cautionary tales, and cross‑cultural governance models into a robust, publicly funded research agenda, we can transform the narrative from one of hype to one of responsible innovation. Inclusive governance bodies, equitable technology transfer, and long‑term safety modelling together address the scientific, ethical, and societal dimensions. Such systemic reform aligns with past precedents where collective oversight curbed premature biomedical rollouts, offering a pathway toward just and safe neuro‑therapeutics.